Form 4: ResMed CFO Brett Sandercock Sells 1,000 Shares Under 10b5-1 Plan
SEC Form 4 Filing
ResMed's Chief Financial Officer, Brett Sandercock, sold 1,000 shares of ResMed Common Stock at a price of $234.04 per share on January 8, 2025, under a pre-arranged 10b5-1 trading plan.
Summary
- On January 8, 2025, Brett Sandercock, the Chief Financial Officer of ResMed Inc., sold 1,000 shares of ResMed Common Stock.
- The sale was executed at a price of $234.04 per share.
- Following the transaction, Sandercock directly owns 92,864 shares of ResMed Common Stock.
- The transaction was conducted under a Rule 10b5-1 plan adopted on February 6, 2024.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing related to an insider stock sale under a pre-arranged plan. It doesn't inherently indicate positive or negative sentiment, but rather a routine transaction.
Industry Context
Sales by company insiders are a common occurrence and are often pre-planned to avoid accusations of insider trading. The use of a 10b5-1 plan allows insiders to sell shares at predetermined times and prices.
Stakeholder Impact
- The sale of shares by a company insider could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| February 6, 2024 | Date the Rule 10b5-1 plan was adopted. |
| January 8, 2025 | Date of the transaction (sale of shares). |
| January 9, 2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.